Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Scilex Holding CompanyNASDAQ: SCLX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $45.65M (cash outflow) rose 75.0% year over year, behind the +410.8% change in trailing-twelve-month net income. Sequentially, it rose 37.9% from the prior quarter. Over 3 fiscal years it compounded at +148.5% a year.
Context
- Net income amounted to 1185.8% of revenue in FY2025, up 1057.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$6.11M (-98.3%) for the fiscal year ending Dec 2026, a slowdown from the +392.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$45.65M+37.9% QoQ
- Last fiscal yearDec 2025
- -$358.73M+392.7% YoY
- LTMMar 2026
- -$380.63M+410.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +75.0% | -97.2% | -172.2 pp |
| 1 year | +392.7% | -98.3% | -491.0 pp |
| 3-year CAGR | +148.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (358.73M) USD
- Year-over-year change
- -392.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (358.73M) | -392.7% |
| FY2024 | 2024-12-31 | (72.81M) | +36.3% |
| FY2023 | 2023-12-31 | (114.33M) | -389.3% |
| FY2022 | 2022-12-31 | (23.36M) | +73.6% |
| FY2021 | 2021-12-31 | (88.42M) | — |
Net Income vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 net income of $380.63M is the 2nd largest of the 9 companies compared; the peer median is $95.93M.
- Its year-over-year change of +410.8% is the 2nd highest of 9, against a peer median of +8.1%.
- Net income amounts to 1124.1% of revenue for SCLX, versus a peer median of 719.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.68B | +43056.2% | +1.1% | 519699.0% | |
| LTM Mar 2026 | $380.63M | +410.8% | +148.5% | 1124.1% | |
| LTM Mar 2026 | $125.39M | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $42.51M | +14.7% | — | 757.6% |
| Peer median (excluding SCLX) | $95.93M | +8.1% | +0.7% | 719.2% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Depreciation & Amortization | 3.78M | 3.96M | 4.15M | 4.05M | 4.62M |
| Deferred Income Tax | 12.76M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.82M | 5.28M | 14.6M | 15.69M | 15.49M |
| Change in Working Capital | 13.6M | 45.67M | 65.8M | 64.84M | 113.97M |
| Accounts Receivables | (1.14M) | (6.97M) | (13.36M) | (6.27M) | 13.84M |
| Inventory | (1.42M) | 1.18M | (2.84M) | 1.46M | 1.8M |
| Accounts Payables | (3.84M) | 2.81M | 19.88M | 7.42M | 13.12M |
| Other Working Capital | 20M | 48.65M | 62.12M | 62.23M | 85.21M |
| Other Non-Cash Items | 23.79M | (52.8M) | 9.08M | 7.58M | 228.47M |
| Operating Cash Flow | (28.66M) | (21.26M) | (20.71M) | 19.35M | 3.82M |
| Capital Expenditures | 0 | (2.07M) | (330K) | (600K) | (133K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (2.08M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (300K) | 0 | 4.22M |
| Investing Cash Flow | 0 | (2.07M) | (330K) | (2.68M) | 4.08M |
| Debt Repayment | (19.69M) | (31.25M) | 728K | (64.21M) | (2.81M) |
| Common Stock Issued | 0 | 96K | 35.46M | 44.64M | 27.88M |
| Common Stock Repurchased | 0 | 0 | (10M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47.85M | 52.33M | (2.6M) | 1.44M | (30.53M) |
| Financing Cash Flow | 28.16M | 21.17M | 23.58M | (18.13M) | (5.46M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (756K) |
| Net Change in Cash | (501K) | (2.15M) | 2.55M | (1.46M) | 1.68M |
| Free Cash Flow | (28.66M) | (23.33M) | (21.04M) | 18.75M | 3.68M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.